Christian democracy

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

11th Annual Emerging Trends in Workplace Wellness Conference Features National Speakers and Trending Topics

Retrieved on: 
Monday, March 11, 2024
Health, Harvard Medical School, Certification, Conference, Learning, Christian democracy, Ecosystem, Workforce, Workweek and weekend, SHRM, Pharmaceutical industry

BOSTON, March 11, 2024 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 11th Annual Emerging Trends in Wellness Conference on April 11th. The event will feature nationally recognized speakers from across the country who highlight the importance of employee well-being, how to become a wellness employer of choice, and key strategies to develop a healthy and resilient workforce.

Key Points: 
  • Wellness Workdays' virtual conference features speakers from Columbia Construction, Culver Pediatrics, Idaho Forest Group, and Other Leading Industry Employers
    BOSTON, March 11, 2024 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 11th Annual Emerging Trends in Wellness Conference on April 11th.
  • "As employee needs continue to evolve, employers now appreciate that wellness interventions are a critical strategic element to a thriving and resilient workforce," said Debra Wein, CEO of Wellness Workdays.
  • In addition to learning from leading industry employers, attendees will also learn from a panel of this year's certified Best Wellness Employers.
  • Wellness Workdays is recognized by SHRM to offer Professional Development Credits (PDCs) for the SHRM-CPSM or SHRM-SCPSM.

Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today

Retrieved on: 
Saturday, January 20, 2024
Molecule, Neoplasm, STAL, Peptide library, AI, Peptide, Toxicity, Metabolism, Christian democracy, Fine chemical

The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Platform (STAL)", with a library capacity of up to 3.05×1012 CFU (30 trillion).

Key Points: 
  • The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Platform (STAL)", with a library capacity of up to 3.05×1012 CFU (30 trillion).
  • Sanyou Biopharmaceuticals has meticulously developed the Super Trillion Peptide Molecule Discovery Platform by collecting and analyzing tens of thousands of natural amino acid sequences.
  • Leveraging years of experience in the filed of innovative biopharmaceuticals and the construction of the STAL Super Trillion Antibody Library platform, Sanyou Biopharmaceuticals has successfully overcome various technical challenges and completed the construction of the Super Trillion Peptide Molecule Discovery Platform.
  • It is believed that the launch of the Sanyou Super Trillion Peptide Molecule Discovery Platform will overcome the development difficulties of peptide drugs, and greatly accelerate the development process of peptide drugs!"

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

Retrieved on: 
Tuesday, December 12, 2023
PDC, Christian democracy, Cancer, Patent, Macroglobulinemia, Flavagline, IP, Pharmaceutical industry

These patent allowances in key global regions follow prior allowances for the same patent in the US, Europe, Australia and Canada.

Key Points: 
  • These patent allowances in key global regions follow prior allowances for the same patent in the US, Europe, Australia and Canada.
  • The patent provides composition of matter and use protection for the Cellectar’s Phospholipid Drug Conjugate™ (PDC) platform as a targeted delivery vehicle in combination with a class of small molecules known as flavaglines.
  • Flavaglines are a family of natural (plant derived) cytotoxic molecules that, when targeted to cancer, have been shown to kill the tumor cells.
  • Our robust global IP portfolio provides the foundation as we drive forward our mission to transform cancer care for people worldwide.”

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Retrieved on: 
Monday, November 27, 2023
Christian democracy, Family, PDC, Antigen, B cell, Immunology, BDCA2, IND, Autoimmunity, Research, Plasma cell, SLE, Inflammation, Half-life, CD122, SAN, Lupus, GMP, CNTA, Monocyte, Patient, Antigen presentation, Therapy, Vaccine

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Key Points: 
  • Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
  • Under the terms of the agreement, Anaptys will receive from Centessa Pharmaceuticals an exclusive, global license for ANB101.
  • Anaptys will also receive the same rights to ANB102, an extended half-life BDCA2 modulator with the potential to enable quarterly or less frequent dosing.
  • Centessa is eligible to receive an additional development milestone payment and low single-digit royalties on global net sales.

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Retrieved on: 
Monday, November 27, 2023
Retail, Health, Fitness & Nutrition, General Health, Vitamins, Supplements, Food, Beverage, Biotechnology, Sale, Capsule, PubMed, Lactococcus lactis, Immunity, Research, Immune system, Kao Corporation, Plasma, Coffee, Government, Polyphenol, Multimedia, Christian democracy, Consumer Affairs Agency, Kirin, Invention, University, BMI, Imperial, Kirin Holdings, IMUSE, Human, Lipid metabolism, Growth, Holding company, Chlorogenic acid, Vaccine, Dietary supplement, Medical device

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).

Key Points: 
  • Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).
  • This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
  • We are developing a broad lineup of functional food products with immune function claims to help customers solve their health issues.
  • “Kirin iMUSE Immunity Care and Healthya Visceral Fat Down,” which is about to go on sale, is a product born from the joint research project.

Learning & HR Tech Solutions Announces Keynote and Session Details

Retrieved on: 
Thursday, December 7, 2023
Shark Tank, SHRM, Learning, ABC, Conference, HR, AI, Christian democracy, L&D

The free-to-attend Expo on April 23-24 includes:

Key Points: 
  • The free-to-attend Expo on April 23-24 includes:
    100+ Solution Providers: Leading Learning & HR technology vendors and start-ups will showcase cutting-edge solutions.
  • 45+ Expo Stage Sessions: Gain insights, strategies, and best practices for navigating the Learning and HR technology landscape.
  • "We are thrilled to host this expanded event for the industry community," said David Kelly, CEO of the Learning Guild.
  • "Our goal is to create a space for learning and HR professionals to prepare themselves for changes shaping the future of talent development."

Global Peptide Drug Conjugates Market Expected to Reach $4.21 Billion by 2030, Driven by Rising Cancer Cases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, Pharmaceutical, WHO, FDA, Clinical trial, Multiple myeloma, Lung cancer, Mortality, Carcinoma, Christian democracy, Death, Wuxi, Lutetium (177Lu) oxodotreotide, Growth, Novartis, World Health Organization, PDC, Partnership, Brain, USD, Cancer, ANG1005, Somatostatin, Melphalan, Compound annual growth rate, Fine chemical, Pharmaceutical industry

The global peptide drug conjugates market is poised for significant growth, with an expected value of USD 4.21 billion by 2030, registering a remarkable Compound Annual Growth Rate (CAGR) of 28.58% during the forecast period.

Key Points: 
  • The global peptide drug conjugates market is poised for significant growth, with an expected value of USD 4.21 billion by 2030, registering a remarkable Compound Annual Growth Rate (CAGR) of 28.58% during the forecast period.
  • Rising Cancer Cases: The market's growth is driven by the global surge in cancer cases and related mortality.
  • The increasing demand for novel treatments like peptide drug conjugates (PDCs) to target uncontrolled cell growth is expected to fuel market growth.
  • For instance, in December 2021, Coherent Biopharma and WuXi STA announced a strategic partnership agreement to develop their current and future therapeutic drugs, including peptide drug conjugates.

Diversity, Equity, and Inclusion Strategies by Slone Partners Receives SHRM Accreditation as a Recertification Provider

Retrieved on: 
Tuesday, October 10, 2023
Momentum, Break Down Barriers, Society for Human Resource Management, SHRM, Christian democracy, Accreditation, Organization, Strategic planning, Society, Health, Education, Marketing, DEI, Best practice, Nursing, Management, Workplace

SOUTH RIDING, Va., Oct. 10, 2023 /PRNewswire-PRWeb/ -- Diversity, Equity, and Inclusion (DEI) Strategies by Slone Partners has received accreditation as a recertification provider by the Society for Human Resources Management (SHRM). As an authorized provider, workshops, events, and other programs delivered by DEI Strategies by Slone Partners will be made available to thousands of human resources (HR) professionals who are required to earn professional development credits (PDCs) to maintain their credentials.

Key Points: 
  • SOUTH RIDING, Va., Oct. 10, 2023 /PRNewswire-PRWeb/ -- Diversity, Equity, and Inclusion (DEI) Strategies by Slone Partners has received accreditation as a recertification provider by the Society for Human Resources Management (SHRM) .
  • "As an authorized provider, we will expand our reach and impact by marketing our valuable set of DEI training programs and events to HR professionals across the country," said Leslie Loveless, CEO of Slone Partners.
  • "It is a significant milestone for us to receive this accreditation from the Society," said Leslie Loveless , CEO of Slone Partners.
  • Candace Nortey , Managing Director of DEI at Slone Partners, said, "Our mission is to guide companies along their DEI journey through specialized recruiting, education, and training.

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Retrieved on: 
Monday, October 2, 2023
PLE, IP Australia, Radiation, Glioma, Intellectual property, Neoplasm, Lung cancer, Christian democracy, IP, Chinese, EPO, PDC, Patent, Patient, Melanoma, CIPO, European Patent Convention, Metastasis, European Patent Office, Glomus tumor, Identification, Canadian Intellectual Property Office, Isolation, Medical imaging, Pharmaceutical industry, Cancer

FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.

Key Points: 
  • FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.
  • This patent significantly enhances the use of iopofosine I 131 for treating various cancers, including gliomas, lung cancer, melanoma, and more, with a focus on cancer stem cells.
  • The Canadian Intellectual Property Office (CIPO), the Australian Patent Office (IP Australia) and the EPO have granted patent number 17814042.2 for "Phospholipid Ether Analogs for the Identification and Isolation of Circulating Tumor Cells".
  • “The expanded protection in these key global regions supplements our existing patent portfolio and the coverage with these patents we have already obtained in the US and other territories.